Overview

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Phase:
Phase 3
Details
Lead Sponsor:
Sprout Pharmaceuticals, Inc